Ignite Creation Date:
2025-12-24 @ 6:29 PM
Ignite Modification Date:
2026-01-28 @ 3:25 PM
Study NCT ID:
NCT00920868
Status:
COMPLETED
Last Update Posted:
2016-02-03
First Post:
2009-06-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
Sponsor:
Herbert Hurwitz, MD
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Phase I | View |
| None | Solid Tumor | View |
| None | Colorectal | View |
| None | Dasatinib | View |
| None | Sprycel | View |
| None | Bevacizumab | View |
| None | Avastin | View |
| None | Oxaliplatin | View |
| None | Eloxatin | View |
| None | Capecitabine | View |
| None | Xeloda | View |
| None | Duke | View |
| None | Any Solid Tumor (Phase I) | View |
| None | Metastatic Colorectal Cancer (Expanded Cohort) | View |